-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta CRYstalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...

-The Times of India CHENNAI: Only three institutes in the country, all of them Indian Institutes of Technology, feature among the top 100 universities in Asia, according to the first Asia University Rankings released by "Times Higher Education" magazine. While IIT-Kharagpur is ranked 30th, IIT-Bombay is 33rd and IIT-Roorkee 56th, the University of Tokyo secured the pole position with an overall score of 78.3, followed by the National University of Singapore...

-Tehelka With 65 percent of the population below the age of 35, India boasts of an unparalleled generational dividend, but are we turning this potential into a disaster? Avalok Langer spots a ticking time bomb Nutrition & Health* 40% of children in India are malnourished 43% of children in the age group of 12-23 months receive full immunisation 48%+ of children are underweight 50%+ of all deaths under age 5 are related to malnutrition 45% of children...

-The Indian Express She was gangraped by 16 boys, nine of them juveniles. She was beaten, cut up and her genitals mutilated. She made it to hospital, but was sent home with first-aid. When she survived to fight, she ran into an indifferent administration and influential accused. Schools denied her admission, and others mocked and threatened her. Chances are you haven't heard this 16-year-old's story. Three days after the brutal attack on...

-The Times of India Big pharma may be CRYing hoarse over India's "weak'' intellectual property environment, but over the past five years or so, they have introduced only a handful of their patented blockbusters in the country. That's not all. The contribution of patented drugs in the Rs 72,000-crore pharma retail market is not even 1%, indicating that multinationals have been traditionally slow and have a poor track record in introducing...